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Apoptosis (programmed cell death) is essential during develop-
ment and in the maintenance of tissue homeostasis, and serves to
delete damaged or redundant cells (Thompson, 1995; Vaux and
Korsmeyer, 1999). Disruption of the normal mechanism for apop-
tosis can result in a number of pathological conditions. The inap-
propriate survival and propagation of cells with damaged DNA
may contribute to the development of neoplasia and metastases
(Sarasin and Stary, 1997). 
Apoptosis is regulated by a wide variety of survival signals
including growth factors, cell adhesion, and by cellular 
mechanisms that monitor DNA integrity (Gilmore et al, 2000;
Hengartner, 2000; Rich et al, 2000; Streuli and Gilmore, 1999).
The absence of survival signals or sensing of DNA damage results
in the activation of caspases, a family of cysteine proteases that
cleave a wide variety of cellular proteins, ultimately leading to the
destruction of the cell. Caspases are present in the cytoplasm as
zymogens, and the initiation of apoptosis results in the cleavage of
the pro-enzyme and the formation of a tetrameric molecule, the
active form of the enzyme (Green, 1998; Ashkenazi and Dixit,
1999). Caspase 3 is a member of this family, which is present in a
wide variety of cells and tissues including breast. 
The apoptosis execution mechanism results in the development
of characteristic morphological features, which include condensa-
tion of the nucleus and chromatin followed by cell shrinkage and
the appearance of cytoplasmic blebs. The cell detaches from its
neighbours and the nucleus fragments (Hall, 1999). DNA is
cleaved into approximately 200 base pair fragments that aggregate
to form well defined dense hyperchromatic bodies called ‘apoptotic
bodies’, and are visible by conventional microscopy. The apop-
totic cells are recognised by the cells of the reticuloendothelial
system and are removed by phagocytosis (Savill and Fadok,
2000). The time taken from the activation of the apoptotic mecha-
nism to cell clearance is approximately 1–3 hours, indicative of the
dynamic nature of the process (Sanderson, 1976; Matter, 1979;
Wyllie et al, 1980; Gavrieli et al, 1992; Hall, 1999). 
The measure for quantification of apoptosis is the apoptotic
index (AI). In an epithelial tissue or carcinoma line, the AI is a
percentage expression of the ratio of the number of apoptotic
events to the total number of the epithelial cells examined (Potten,
1996; Lipponen, 1999). Various methods are used for the detection
of cells undergoing apoptosis and these methods include 
morphological assessment, in situ end labelling (ISEL), terminal-
deoxynucleotidyl-transferase-mediated dUTP nick end labelling
(TUNEL) and the use of a monoclonal antibody to single-stranded
DNA (Frankfurt et al, 1997; Mainwaring et al, 1998). However,
each of these methods has significant limitations. The quantifica-
tion of apoptotic events by morphological assessment depends on
the examiner’s subjective assessment in order to accurately iden-
tify apoptotic cells. Accurate distinguishing features of apoptosis
for morphological assessment also tend to be late events and are
only apparent for a brief window of time, therefore leading to
lower scores of apoptosis than actually occurs. TUNEL, on the
other hand, fails to distinguish apoptosis from necrosis, and only
detects late stages of the process, and furthermore can produce
artefactual positive results where nuclei are cut during the
sectioning procedure (Grasl-Kraupp et al, 1995; Frankfurt et al,
1997). 
In this study, we have examined apoptosis in mammary epithelia
by immunohistochemistry using an antibody specific for the active
form of caspase 3. We compared this with the morphological
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Summary Apoptosis is of important significance in the pathogenesis of cancer. Many methods are available for the measurement of
apoptosis but the ‘gold standard’ is to identify apoptotic cells by their morphological features using microscopy. Caspase 3 is a cytosolic
enzyme that is activated only in cells committed to undergo apoptosis. The activation of caspase 3 precedes the development of the classical
morphological features of apoptosis. Using immunohistochemistry with an antibody against the active form of caspase 3, the apoptotic index
(AI) was measured in 116 samples of human breast tissue (22 normal/benign and 94 invasive carcinomas). The AI obtained by measuring
caspase activation has a strong correlation with the AI derived by morphological assessment (r = 0.736, P < 0.01). The AI is higher in the
invasive group than in the benign group (P = 0.008), and in invasive cancer high AI is associated with high tumour grade (P = 0.013), positive
node status (P < 0.001) and negative steroid receptor status (P = 0.001 for ER; P = 0.004 for PR). No significant association is observed
between AI and tumour size. Measurement of apoptosis by immunohistochemistry using an antibody against the active form of caspase 3 is
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method for the examination of apoptosis (Hall, 1999). Furthermore,
we correlated apoptosis derived by both immunohistochemistry
and morphological assessment with tumour histopathological
characteristics. Our results demonstrate higher levels of apoptosis
in invasive, node-positive, breast cancer than benign breast 
disease. 
MATERIALS AND METHODS 
Tissue 
Samples of benign breast tissue and invasive breast carcinomas
were randomly selected from the archives at the Manchester Breast
Unit. Permission to collect normal breast tissue from patients under-
going surgery in the Unit was granted by the South Manchester
Ethical Committee and all patients gave written informed consent.
The histopathological characteristics for most of the tumours
including histological type, size, grade and axillary lymph node
status were available following the routine histological examination
of the excised specimen immediately following surgery. Clinical
information of these patients was also available from a large data-
base. The tissue was embedded in paraffin and, using a microtome,
serial consecutive sections 7 µ m in thickness were obtained and
mounted in APES-coated slides. One section from each sample was
stained with haematoxylin and eosin for morphological assessment
of apoptosis. Immunohistochemistry was performed on the next
consecutive section.
Immunohistochemical staining for active caspase 3 
The sections were deparaffinised in xylene and rehydrated in
ethanol of increasing dilution. The sections were then treated with
0.3% Triton-X100 for 15 minutes and non-specific binding sites
were blocked with goat serum. The sections were washed with 0.1%
bovine serum albumin (BSA) diluted in phosphate buffer saline
(PBS). A rabbit polyclonal primary antibody against the active form
of caspase 3 (R&D systems, Abingdon, Oxfordshire) was then
applied to the sections at a concentration of 1:1000 diluted in goat
serum for 1 hour at 37˚C in a moist chamber. Following three 5-
minute washes with 0.1% BSA/PBS the sections were treated with
0.03% hydrogen peroxide containing sodium azide (DAKO
EnVision+ System). The sections were washed once for 5 minutes
and a peroxidase-labelled polymer conjugated to goat anti-rabbit
secondary antibody (DAKO) was applied for 30 minutes at 37˚C.
One 5-minute wash with 0.1% BSA/PBS and two 5-minute washes
with plain PBS followed and the AEC (3-amino-9-ethylcar-
bazole)/substrate-chromogen (DAKO) was applied for 15 minutes.
The sections were washed in distilled water and glass coverslips
were mounted using glycerol. The negative controls were treated in
the same way omitting the primary antibody, which was substituted
with goat serum. For positive controls, sections from tumours
known to have very high apoptotic activity were used. 
Assessment of apoptosis 
The AI was calculated as a percentage of the apoptotic cells out of
the total number of cells examined. The AI was obtained by
morphological assessment of the H&E stained sections or by
examination of the sections stained using immunohistochemistry.
In the former assessment, the classical characteristics of apoptosis
were used as the criteria for the identification of the apoptotic cells
and in the latter all the identifiable cells exhibiting staining were
counted (Figure 1). Control studies using primary cultures of
mammary epithelial cells indicate almost complete coincidence of
apoptosis measured by altered nuclear morphology and by
immunostaining for active caspase 3 (data not shown). Apoptotic
cells that were present in areas where intense necrosis had
occurred were excluded from the analysis. 
Immunostaining for oestrogen receptor 
Following deparaffinisation with xylene and blocking of the
endogenous peroxidase activity by incubation with 0.3% hydrogen
peroxide, non-specific binding was blocked with 20% normal rabbit
serum (DAKO X902) for 15 minutes. Primary antibody (1:100 dilu-
tion of mouse monoclonal anti-human ER; DAKO M7047) was
applied overnight at 4˚C. A biotinylated rabbit anti-mouse
immunoglobulin (DAKO E413) was applied as the secondary anti-
body (1:350 dilution) for 1 hour. Streptavidin (DAKO) was applied
for 30 minutes and sections were visualised with DAB (Abbott
Diagnostics). Sections where 5% or more of cells showed staining
for oestrogen receptor (ER) were considered as positive.
Immunostaining for progesterone receptor 
Following blocking of the non-specific binding and endogenous
peroxidase activity, the section was treated with a rat monoclonal
A
B
Figure 1 (A) A section of invasive breast cancer stained with haematoxylin
and eosin. The apoptotic cell (arrow) is identified by the presence of the
rounded, densely stained ‘apoptotic bodies’ which represent parts of the
fragmented nucleus. (B) A section of invasive breast cancer stained by
immunohistochemistry with a primary antibody against the active form of
caspase 3. The red orange staining of the apoptotic cell (arrow) makes its
identification easier 1524 I Hadjiloucas et al 
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antibody PgR-ICA (Abbott Diagnostics) at a dilution 1:4
overnight. Following rinsing, sections were incubated with
biotinylated rabbit anti-rat antibody (1:100 dilution) for 30
minutes at room temperature. Sections were treated with
Streptavidin for 30 minutes and visualised with DAB. Sections
where 5% or more of cells showed staining for progesterone
receptor (PR) were considered as positive. 
Light microscopy 
All sections were examined within 48 hours of staining. A 40 ×
objective lens was used with a 10× eyepiece lens and at least 1000
epithelial cells were examined in every section. The same topo-
graphical areas were examined in consecutive sections of the same
sample in order to minimise tissue heterogeneity. Areas of intense
necrosis or apoptosis were excluded as this would have produced a
non-representative result. 
Statistical analysis 
All the statistical analysis of the results was performed using the
statistical package for social science (SPSS) under the guidance of
a professional statistician. 
RESULTS 
22 samples of normal breast tissue (2 samples from reduction
mammoplasty specimens and 20 samples from women undergoing
surgery for benign breast disease) and 94 primary invasive breast
carcinomas were examined in this study. The mean age group of the
subjects was 57.3 years with a range from 16 to 84 years (Table 1). 
To evaluate if there was a correlation between morphological
and immunohistochemical analysis of apoptosis, AI values using
both methods were obtained for every sample and plotted as a
scatter diagram (Figure 2). The overall Spearman’s correlation
coefficient (n = 116) between these 2 variables is 0.736 (P value <
0.01). This indicates a strong correlation between the 2 methods
and demonstrates that caspase staining produces similar apoptosis
data to the method of morphological assessment. 
To determine if apoptosis relates to breast cancer aggressiveness
we measured the AI in tissue from 94 cancer patients and compared
apoptosis levels amongst the known breast cancer prognostic indica-
tors. First, the AI was lower in normal/benign breast tissue compared
to the invasive group of samples, the difference in the AI values
being statistically significant (P = 0.008) (Figure 3A). Second, the
median AI in the node-positive group of breast cancers was signifi-
cantly (P < 0.001) higher than the corresponding value in the node-
negative group (Figure 3B). Third, grade III tumours had a higher AI
than grade I or II tumours (P = 0.013) (Figure 3C). Finally, a signifi-
cantly higher AI (P = 0.009) was found in the ER-negative group of
tumours than the ER-positive group (Figure 3D). The same trend
was observed with the progesterone receptor (AI = 0.54 for PgR
negative vs 0.185 for PgR positive; P = 0.05) (data not shown).
Together these data indicate that substantially more apoptosis is
detected in breast cancer than in the normal tissue. 
DISCUSSION 
There are 2 important conclusions to be drawn from this study. The
first is that, by taking advantage of the activation of caspase 
3 during apoptosis, we have developed a robust method for
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Figure 2 Comparison of the morphological and immunohistochemical
methods of apoptosis assessment. Parallel sections of all the tissue samples
were scored for apoptosis both by immunostaining for activated caspase-3
(A1:IHC) 0.20 (0–0.55) and by using the conventional method of assessing
nuclear morphology (AI:morph) 0.27 (0.08–0.54) 
Table 1 (a) Characteristic features of the normal/benign breast disease
group. (b) Characteristic features of the tumour group 
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that significantly more apoptosis occurs in breast carcinoma than
in normal or benign breast tissue and that apoptosis is higher in the
more invasive cancers. 
The appearance of the active form of caspase 3 in the cytoplasm
of the cells undergoing apoptosis is an early event and precedes 
the development of the classical morphological features of 
apoptosis. Hence, immunohistochemistry using an antibody
against the active form of caspase 3 detects cells undergoing 
apoptosis at an early stage. The bright orange staining of apop-
totic cells in light microscopy, using this method, makes the
detection of apoptotic cells in the section easy and less dependent
on the observer’s subjective opinion. Non-specific back-
ground staining was minimal in the protocol described. A very
small number of cells, less than 0.01%, showed morpho-
logical features of apoptosis but no staining, and in this study 
they were not included in the analysis. A similar finding has 
also been observed in a previous study with TUNEL and in-
situ nick translation, and is expected as some cells may 
undergo apoptosis without the activation of caspase 3
(Mainwaring et al, 1998). 
The apoptotic indices obtained by the 2 methods show strong
correlation, indicating that assessing apoptosis by immunohisto-
chemistry using an antibody to the active form of caspase 3 is an


























































Figure 3 (A) Comparison of the AI between normal/benign breast and invasive carcinoma. In each case, the number of samples analysed is shown in
brackets below the bars, and the median AI value is shown within the bars. Similar results were obtained using both caspase-3 and morphological methods of
apoptosis assessment. (B) Comparison of the apoptotic indices in the lymph node positive and negative groups of tumour tissue. (C) Comparison of the
apoptotic indices between tumour grades. (D) Comparison between the oestrogen receptor (ER)-positive and-negative groups. Sections where more than 5% of
cells exhibited ER staining were categorised as positive and those where less than 5% of cells exhibited staining as negative
Table 2 Comparison of our study with others measuring the apoptotic index
AI in primary invasive breast carcinomas using different methods of
assessment and different units of measurement. (a) Studies where AI is
calculated as a percentage of the total number of cells counted. (b) Studies
where AI is calculated per unit area of tissue examined 
Author Method Unit Mean
AI
a Frankfurt Mab ss-DNA (% Apoptotic cells/Total 5.5 
(1997) number of cells examined) 
Frankfurt TUNEL (% Apoptotic cells/Total 0.74 
(1997) number of cells examined) 
Vakkala ISEL (% Apoptotic cells/Total  0.74 
(1999) number of cells examined) 
Harn (1997) ISEL (% Apoptotic cells/Total 0.36 
number of cells examined) 
This study active caspase-3 (% Apoptotic cells/Total 0.33 
staining number of cells examined) 
b Rochaix TUNEL Apoptotic cells mm–2 9.7 
(1999)
Lipponen H&E Apoptotic cells mm–2 11.3 
(1994)
Zhang (1998) H&E Apoptotic cells mm–2 11.0 
Zheng (1998) H&E Apoptotic cells mm–2 11.14 1526 I Hadjiloucas et al 
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easy to apply and free of subjective interpretation, and therefore
does not require an experienced observer trained to recognise
apoptotic cells in tissue sections. It also does not rely on DNA
fragmentation, a late event in the apoptotic process. Thus we
recommend that this method should be adopted more widely in the
study of apoptosis in breast cancer. 
We have found that a high AI is associated with node positivity
and oestrogen receptor negativity in breast cancer. The AI 
is highest in the poorly differentiated grade III tumours. Other
studies have shown that higher apoptosis is associated with 
grade III tumours, strengthening the findings in this study
(Lipponen et al, 1994; Frankfurt et al, 1997; Zheng and Zhan,
1998; Rochaix et al, 1999). We found no association between the
AI and tumour size, supporting the results of 2 earlier studies
(Lipponen et al, 1994; Berardo et al, 1998). 
Our results compare well with other studies (Table 2), where
high levels of apoptosis have also been associated with high
tumour grade, lack of tubule formation, increased risk of lymph
node metastasis, and loss of steroid receptors (Lipponen et al,
1994; Frankfurt et al, 1997; Zhang et al, 1998; Zheng and Zhan,
1998; Rochaix et al, 1999). In one study, the AI was shown to be
associated with shorter recurrence-free survival (Lipponen et al,
1994). In another study, the AI was found to be a predictor of
survival in univariate analysis but failed to do so in multivariate
analysis. Recurrent tumours had significantly higher proliferation
and apoptosis compared to primary tumours and correlated with
reduced patient survival (Vakkala et al, 1999). 
Together, these results demonstrate that AI is higher in carci-
noma tissue than in benign breast epithelium. It is well known that
proliferation rates increase in carcinoma, and the finding that
apoptosis rates are also higher is suggestive of a tissue that is much
more rapidly turning over. The increases in apoptosis may be
indicative of substantial genomic instability that is manifested
during breast cancer progression. 
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